Purpose Overexpression of CD105 (endoglin) correlates with poor prognosis in many solid tumor types. Tumor microvessel density (MVD) assessed by CD105 staining is the current gold standard for evaluating tumor angiogenesis in the clinic. The goal of this study was to develop a positron emission tomography (PET) tracer for imaging CD105 expression.
Introduction
Over the last decade, molecular imaging of angiogenesis has gained tremendous interest since angiogenesis is a fundamental process in both normal physiology and many disease processes such as tumor development and metastasis [1, 2] . Two of the most intensively studied angiogenesis-related targets are integrin α v β 3 and vascular endothelial growth factor receptors (VEGFRs). Several tracers targeting these two receptors are already in clinical investigation [3] [4] [5] . Another attractive target related to tumor angiogenesis is CD105, also known as endoglin. CD105 is a disulfide-linked homodimeric transmembrane protein with a molecular weight of 180 kDa, composed of short intracellular and transmembrane domains and a large extracellular region [6, 7] .
CD105 is considered to be the most suitable marker for evaluating tumor angiogenesis [8, 9] . Levels of CD105 expression in the endothelia within neoplastic tissues correlate with the proliferation rate of endothelial cells [10, 11] . Studies have revealed that CD105 is overexpressed in vascular endothelial cells of tissues undergoing angiogenesis (e.g., tumors or regenerating/inflamed tissues) [10] [11] [12] . High CD105 expression also correlates with poor prognosis in more than ten solid tumor types, consistent with the increased vascular proliferation rate required for rapidly proliferating cancers [13] [14] [15] . These findings support the role of CD105 as an optimal marker of tumor angiogenesis, underscoring its emerging clinical potential as a prognostic, diagnostic, and therapeutic vascular target in cancer.
CD105-targeted imaging agents could represent a new paradigm for the assessment of antiangiogenic therapeutics, thereby facilitating the understanding of the role and expression profile of CD105 in angiogenesis-related diseases [13, 15, 16] . Molecular imaging techniques that have targeted CD105 include molecular magnetic resonance imaging [17] , single photon emission computed tomography (SPECT) [11, 18, 19] , and ultrasound [20] [21] [22] . Another study investigated a 177 Lu-labeled anti-CD105 antibody for potential radioimmunotherapy applications [23] . All of these studies are based on conjugating various imaging or therapeutic labels (e.g., radioisotopes such as 111 In/ 99m Tc/ 125 I/ 177 Lu, Gd-diethylenetriaminepentaacetic acid (DTPA) liposomes, or microbubbles) to anti-CD105 monoclonal antibodies (e.g., MAEND3, E9, and MJ7/18). To the best of our knowledge, positron emission tomography (PET) imaging of CD105 expression has not been previously studied. The excellent sensitivity, superb tissue penetration, and accurate quantification capability of PET warrant the development of a PET tracer for CD105 imaging in preclinical tumor models as well as for future clinical investigation.
TRC105 is a human/murine chimeric IgG1 monoclonal antibody which binds to both human and murine CD105 (with lower affinity to the latter) and inhibits angiogenesis and tumor growth. The murine parent antibody of TRC105 has been shown to induce apoptosis of human endothelial cells [24] , mediate transforming growth factor (TGF)-β-dependent inhibition of human endothelium [25] , and inhibit the growth of syngeneic murine tumor grafts [26] . Compared with other anti-CD105 antibodies, TRC105 has a very high avidity (with a K D of 2 ng/ml) for human CD105 and is currently in a multicenter phase 1 first-inhuman dose-escalation trial in the USA [27] . Multiple phase 2 therapy trials are planned or underway in patients with various solid tumor types. In this study, we conjugated TRC105 with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and investigated the resulting DOTA-TRC105 conjugate both in vitro and in vivo.
Materials and methods

Reagents
TRC105 (a human/murine chimeric IgG1 monoclonal antibody which binds to CD105) was provided by TRACON Pharmaceuticals Inc. (San Diego, CA, USA). Cetuximab (a human/murine chimeric IgG1 monoclonal antibody that binds to human epidermal growth factor receptor (EGFR) but does not cross-react with the murine EGFR, http://www.accessdata.fda.gov/drugsatfda_docs/bla/ 2004/125084_ERBITUX_PHARMR_P1.PDF) was from Bristol-Meyers Squibb Company (Princeton, NJ, USA). AlexaFluor488-and Cy3-labeled secondary antibodies were purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, CA, USA). DOTA-NHS was purchased from Macrocyclics, Inc. (Dallas, TX, USA) and Chelex 100 resin (50-100 mesh) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Water and all buffers were Millipore grade and pretreated with Chelex 100 resin to ensure that the aqueous solution was heavy metal free. PD-10 desalting columns were purchased from GE Healthcare (Piscataway, NJ, USA). 64 Cu was produced via a 64 Ni (p,n) 64 Cu reaction using a cyclotron at the University of Wisconsin-Madison.
Cell lines and animal model 4T1 murine breast cancer, MCF-7 human breast cancer, and human umbilical vein endothelial cells (HUVECs) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). 4T1 and MCF-7 cells were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum and incubated at 37°C with 5% CO 2 . HUVECs were cultured in M-200 medium (Invitrogen, Carlsbad, CA, USA) with 1× low serum growth supplement (Cascade Biologics, Portland, OR, USA) and incubated at 37°C with 5% CO 2 . Cells were used for in vitro and in vivo experiments when they reached~80% confluence.
All animal studies were conducted under a protocol approved by the University of Wisconsin Institutional Animal Care and Use Committee. For the 4T1 tumor model, 4-to 5-week-old female Balb/c mice were purchased from Harlan (Indianapolis, IN, USA) and tumors were established by subcutaneously injecting 2×10 6 cells, suspended in 100 μl of 1:1 mixture of RPMI 1640 and Matrigel (BD Biosciences, Franklin Lakes, NJ, USA), into the front flank of mice [28] . The tumor sizes were monitored every other day and the animals were subjected to in vivo experiments when the diameter of the tumors reached 6-8 mm (typically 7-10 days after inoculation).
DOTA conjugation and 64 Cu labeling
Detailed procedures for DOTA conjugation have been reported previously [29, 30] . DOTA-TRC105 and DOTAcetuximab were purified using PD-10 columns and the final concentrations of DOTA-TRC105 and DOTAcetuximab were measured based on UV absorbance at 280 nm using known concentrations of unconjugated TRC105 or cetuximab as the standard. For radiolabeling, 64 CuCl 2 (74 MBq) was diluted in 300 μl of 0.1 M sodium acetate buffer (pH 6.5) and added to 50 μg of DOTA-TRC105 or DOTA-cetuximab. The reaction mixture was incubated for 30 min at 40°C with constant shaking. 64 Cu-DOTA-TRC105 and 64 Cu-DOTA-cetuximab were purified using PD-10 columns with phosphate-buffered saline (PBS) as the mobile phase. The radioactive fractions containing 64 Cu-DOTA-TRC105 or 64 Cu-DOTA-cetuximab were collected and passed through a 0.2-μm syringe filter for in vivo experiments.
Flow cytometry and microscopy
The immunoreactivity of TRC105 and DOTA-TRC105 to HUVECs (high CD105 expression [11, 31] ) and MCF-7 (CD105-negative [11] ) cells was evaluated by flow cytometry. Briefly, cells were harvested and suspended in cold PBS with 2% bovine serum albumin (BSA) at a concentration of 5×10 6 cells/ml. The cells were incubated with TRC105 or DOTA-TRC105 (1, 5, or 10 μg/ml) for 30 min at room temperature (RT), washed three times with cold PBS, and centrifuged at 1,000 rpm for 5 min. The cells were then incubated with AlexaFluor488-labeled goat antihuman IgG for 30 min at RT. Afterwards, the cells were washed and analyzed by flow cytometry using a BD FACSCalibur 4-color analysis cytometer equipped with 488-and 633-nm lasers (Becton-Dickinson, San Jose, CA, USA) and FlowJo analysis software (Tree Star, Inc., Ashland, OR, USA). HUVECs were also incubated with TRC105 or DOTA-TRC105 (2 μg/ml) and then examined under a Nikon Eclipse Ti microscope to further validate the FACS results.
MicroPET, microPET/microCT, and biodistribution studies PET scans were performed using a microPET/microCT Inveon rodent model scanner (Siemens Medical Solutions USA, Inc., Hoffman Estates, IL, USA). Each tumor-bearing mouse was injected with 5-10 MBq of the PET tracer via tail vein and 3-to 15-min static PET scans were performed at various time points post-injection (p.i.). The images were reconstructed using a maximum a posteriori (MAP) algorithm, with no attenuation or scatter correction. For each microPET scan, three-dimensional (3-D) regions of interest (ROIs) were drawn over the tumor and major organs by using vendor software (Inveon Research Workshop; IRW) on decay-corrected whole-body images. Assuming a tissue density of 1 g/ml, the ROIs were converted to MBq/g using a conversion factor (predetermined using a 50 ml centrifuge tube filled with 64 CuCl 2 as a phantom) and then divided by the administered radioactivity to obtain an image ROI-derived percentage injected dose per gram of tissue (%ID/g). A 4T1 tumor-bearing mouse was injected with 2 mg of unlabeled TRC105 at 2 h earlier than 64 Cu-DOTA-TRC105 administration to evaluate the CD105 specificity of the tracer in vivo (i.e., blocking experiment). As an isotype-matched control, 64 Cu-DOTA-cetuximab (5-10 MBq), was intravenously injected into tumorbearing mice and microPET scans were carried out as described above. After the PET scans, the mice were euthanized. The 4T1 tumor, liver, and spleen (tissues with high uptake of the tracer) were harvested for immunofluorescence staining.
To anatomically localize the tracer signal obtained using PET, a few animals were also subjected to microCT scans. Immediately after PET scanning, animals were transported to the microCT scanning gantry, positioned, and scanned at a voxel resolution of 97 μm (scanning time: 7 min). Fiducial markers were used for coregistration and images were reconstructed using the built-in software (Inveon Acquisition Workshop; Siemens). The microCT and micro-PET data sets were loaded into IRW and fiducial markers were coregistered for alignment of data sets.
Biodistribution studies were carried on a subset of animals to confirm that the quantitative tracer uptake values based on microPET imaging truly represented the actual tracer distribution in tumor-bearing mice. After the last PET scans at 48 h p.i., mice were euthanized and blood, 4T1 tumor, and major organs/tissues were collected and wet weighed. The radioactivity in the tissue was measured using a gamma counter (Perkin Elmer) and presented as % ID/g (mean±SD).
Immunofluorescence staining
Frozen tissue slices (5 μm thickness) were fixed with cold acetone for 10 min and dried in the air for 30 min. After rinsing with PBS and blocking with 10% donkey serum for 30 min at RT, the slices were incubated with TRC105 (2 μg/ml) for 1 h at 4°C and visualized using AlexaFluor488-labeled goat anti-human secondary antibody. The tissue slices were also stained for endothelial marker CD31 (platelet/ endothelial cell adhesion molecule; PECAM) as described previously [32] . After washing with PBS, the slides were incubated with rat anti-mouse CD31 antibody (2 μg/ml) for 1 h, followed by Cy3-labeled donkey anti-rat IgG for 30 min. All images were taken with a Nikon Eclipse Ti microscope.
Statistical analysis
Quantitative data were expressed as mean±SD. Means were compared using Student's t test; p values<0.05 were considered statistically significant.
Results
In vitro investigation of DOTA-TRC105
As shown in Fig. 1 , DOTA conjugation of TRC105 did not alter its CD105 binding affinity, as evidenced by both FACS analysis and fluorescence microscopy. In FACS analysis of HUVECs (which express a high level of CD105), there were no observable differences between TRC105 and DOTA-TRC105 at 1 μg/ml or 5 μg/ml (Fig. 1a) . The binding to HUVECs was specific, as neither TRC105 nor DOTA-TRC105 bound to CD105-negative MCF-7 cells, even at a much higher concentration of 10 μg/ ml (Fig. 1a) . In addition to FACS analysis, fluorescence microscopy was also performed on HUVECs. No significant differences between TRC105 and DOTA-TRC105 were observed (Fig. 1b) . Taken together, these in vitro studies confirmed that DOTA conjugation does not alter the antigen binding avidity or specificity of TRC105. 64 Cu labeling 64 Cu labeling including final purification using PD-10 columns took 80±10 min (n=10). The decay-corrected radiochemical yield was>90% based on 25 μg of protein (DOTA-TRC105 or DOTA-cetuximab) per 37 MBq of 64 Cu, and the radiochemical purity was>98%. The specific activity of both 64 Cu-DOTA-TRC105 and 64 Cu-DOTAcetuximab was about 3.0 GBq/mg protein, assuming virtually complete recovery of the protein after size exclusion chromatography. Based on the specific activity of 64 Cu (~5% of the theoretical value of 254 Ci/μmol) and the amount of DOTA-TRC105 or DOTA-cetuximab used for radiolabeling, it was calculated that there were 0.42± 0.04 (n=3) 64 Cu ions per antibody molecule (TRC105 or cetuximab).
MicroPET studies Based on our previous studies with 64 Cu-labeled antibodies [29, 30, 33] , the time points of 4, 24, and 48 h p.i. were chosen for serial PET scans after intravenous tracer injection. The coronal slices that contain tumors are shown in Fig. 2a and representative microPET/microCT fused images of a mouse at 24 h p.i. of 64 Cu-DOTA-TRC105 are shown in Fig. 2b . The quantitative data obtained from ROI analysis are shown in Fig. 2c, d . Consistent with our previous findings of radiolabeled antibodies, the uptake of 64 Cu-DOTA-TRC105 in the liver (due to hepatic clearance and some transchelation of 64 Cu) and blood pool (due to long circulation lifetime of the antibody) was prominent at early time points and gradually declined over time. The liver uptake of 64 Cu-DOTA-TRC105 was 26.6±2.2, 12.8 ± 0.7, and 9.6 ± 0.6%ID/g at 4, 24, and 48 h p.i., respectively, while the radioactivity in the blood was 16.5±1.3, 8.0±1.5, and 6.5±1.4%ID/g at 4, 24, and 48 h p.i., respectively (n=3, Fig. 2c ). The tumor uptake of 64 Cu-DOTA-TRC105 was clearly visible at 4 h p.i. and plateaued after 24 h p.i. (8.0±0.5, 10.4±2.8, and 9.7± 1.8%ID/g at 4, 24, and 48 h p.i., respectively; n=3; Fig. 2c, d ), indicating antigen-specific binding. Administrating a blocking dose of TRC105 2 h before 64 Cu-DOTA-TRC105 injection reduced the tumor uptake to background level (Fig. 2a, d ), which indicated CD105 specificity of the tracer in vivo.
To further investigate the CD105 specificity of 64 Cu-DOTA-TRC105, 64 Cu-DOTA-cetuximab was used as an isotype-matched control. Both TRC105 and cetuximab are human/murine chimeric IgG1 monoclonal antibodies. Since cetuximab does not cross-react with murine tissues, it serves as an excellent control for investigating the tracer uptake in the tumor due to passive targeting only (i.e., the enhanced permeability and retention effect). As can be seen in Fig. 2a, d , the uptake of 64 Cu-DOTA-cetuximab is at the background level (< 2.5%ID/g) and significantly lower than that of 64 Cu-DOTA-TRC105 at all three time points examined (p<0.05; n=3), which further confirmed the CD105 specificity of 64 Cu-DOTA-TRC105 in vivo.
Biodistribution studies
After the last PET scans at 48 h p.i., the mice were euthanized. The tissues were collected for biodistribution and immunofluorescence staining studies to further validate the in vivo PET data. A separate group of three mice were injected with 64 Cu-DOTA-TRC105 and euthanized at 24 h p.i. for biodistribution studies (Fig. 3a) . Besides the liver and spleen, the kidneys also had significant tracer uptake at 24 h p.i.; however, the absolute uptake was less than that of the 4T1 tumor. Tracer uptake in all other tissues was lower than the tumor. Comparing the biodistribution data at 24 and 48 h p.i., uptake in most tissues dropped significantly yet the tumor uptake remained prominent with little decline, which was indicative of specific interactions between an antibody and its antigen. At 48 h p.i., the tumor uptake was higher than all major organs in the mice, thus providing good contrast. The tumor to muscle ratio was 22.1±1.5 and 25.2±1.2 at 24 and 48 h p.i., respectively (n=3). 64 Cu-DOTA-cetuximab was higher in most organs except the 4T1 tumor (Fig. 3b) , which again indicated the tumor specificity of 64 Cu-DOTA-TRC105. Overall, the quantification results obtained from biodistribution studies and PET scans matched very well, confirming that quantitative ROI analysis of noninvasive microPET scans truly reflected the distribution of PET tracers in vivo.
Histology
Immunofluorescence CD105/CD31 staining of various tissues ex vivo revealed that CD105 expression in the 4T1 tumor was primarily on the tumor vasculature, as evidenced by excellent colocalization of CD105 and CD31 staining and very weak signal on the 4T1 tumor cells (Fig. 4) . CD105 staining of mouse liver and spleen both gave very low signal, indicating that these tissues do not have a significant level of CD105 expression (Fig. 4) . Therefore, tracer uptake in the liver and spleen was largely unrelated to CD105 binding and more likely related to nonspecific capture by the reticuloendothelial system, hepatic clearance, and possibly transchelation of 64 Cu. Taken together, the ex vivo findings corroborated the in vivo data of 64 Cu-DOTA-TRC105, warranting further investigation of this tracer.
Discussion
The currently accepted standard method for quantifying angiogenesis is to assess tumor microvessel density (MVD) by performing CD105 immunohistochemistry on tumor tissue, an independent prognostic factor for survival in patients with many types of solid tumors [15, 34, 35] . CD105 has the advantage of being selectively expressed on proliferating endothelial cells at significantly higher levels (up to 3×10 6 copies per cell) than other angiogenesisrelated targets such as the VEGFRs (less than 0.2×10 6 copies per cell) [31] . Noninvasive imaging of CD105 expression has the potential to accelerate drug development by providing a reliable measure of angiogenesis in the entire body as an intact system, thereby facilitating individualized treatment monitoring and dose optimization in animal models, clinical trials, and ultimately in the dayto-day management of cancer patients. Therefore, the goal of this study was to develop a CD105-specific PET tracer. We have achieved this goal and investigated TRC105 and its conjugates in vitro, in vivo, and ex vivo.
The rationale for choosing the 4T1 tumor model for this study is that the parent antibody of TRC105 (SN6j, a monoclonal antibody of murine origin which binds to CD105) has been shown to be effective as an antiangiogenic agent in this model [26] . Further, this is a rapidly growing tumor model. Thus, it has highly angiogenic tumor vasculature (Fig. 4) which is expected to provide sufficient target density for imaging applications. One limitation of this model is that the tumor vasculature is of murine origin. TRC105 has significantly higher affinity to human CD105 than its murine homolog [36] . Thus, the 4T1 tumor model is not optimal for testing TRC105. Compared with other antibody-based PET tracers, tumor accumulation in this study is relatively low (~10%ID/g). This is largely due to two facts: the tracer targets tumor vasculature but not tumor cells (there are fewer tumor vascular endothelial cells than tumor cells which are the target of most antibodies used for tumor imaging) and the suboptimal affinity of TRC105 to murine endothelial cells relative to human endothelial cells. For future investigation, the following strategies may be adopted to better mimic the clinical situation: stably transfect 4T1 cells with human CD105, use transgenic mice with human tumor vasculature, or test an anti-CD105 antibody that binds with high affinity to murine CD105. Follow-up studies are currently underway. Nonetheless, excellent tumor contrast was achieved in this study, which justifies optimism that this tracer may perform better in cancer patients than we see here in mouse models of cancer.
The stability of radiometal-labeled antibody in vivo is always a concern. Many chelators have been investigated for 64 Cu labeling and DOTA is one of the most intensively studied [37] . To confirm that the tumor uptake of 64 Cu-DOTA-TRC105 as observed in the in vivo studies was indeed antigen specific, various control experiments (e.g., blocking, an isotype-matched control) and in vitro/ex vivo experiments (e.g., FACS, microscopy, and histology) were performed to validate this aspect. We also plan to investigate other chelators (e.g., NOTA, TETA, among others) for 64 Cu labeling in the future and compare the findings with the DOTA conjugates. One advantage of DOTA is that it is a universal chelator which can complex a wide variety of imaging and therapeutic radioisotopes. The same DOTA conjugate can therefore be employed for both imaging and therapeutic applications, with the use of appropriate radioisotopes, without affecting the pharmacokinetics and tumor targeting efficacy of the antibody conjugate.
One of the most interesting findings from this study was the difference between biodistribution patterns of 64 Cu-DOTA-TRC105 and 64 Cu-DOTA-cetuximab at 48 h p.i. The uptake of 64 Cu-DOTA-cetuximab is higher in most organs except the 4T1 tumor (Fig. 3b) . Such an obvious difference between isotype-matched antibodies (both are human/murine chimeric IgG1 type) is likely due to the lack of cross-reactivity with murine tissues for cetuximab, which leads to longer circulation half-life and slower clearance/ sequestration than TRC105 (which cross-reacts with murine CD105 although with lower affinity than human CD105). The overall charge of the two antibodies may also have played a role.
The advantages of antibody-based tracers are that they are quite antigen specific and have high binding affinity and absolute tumor uptake, which makes them suitable for internal radiotherapy applications and/or targeted delivery of drugs. To provide more insight about the long-term Immunofluorescence CD105/CD31 double staining of the 4T1 tumor, liver, and spleen tissue sections. a TRC105 and AlexaFluor488-labeled goat anti-human IgG was used for CD105 staining (green). Afterwards, the tissue slices were stained with rat anti-mouse CD31 antibody and Cy3-labeled donkey anti-rat IgG (red). b A higher magnification merged image revealed that CD105 expression in the 4T1 tumor was almost exclusively on the vessels, evidenced by almost perfect overlay of the CD105 and CD31 staining behavior of TRC105 in vivo, other longer lived isotopes (e.g., 89 Zr, 74 As, etc.) may be explored in future studies. The major limitations of antibody-based imaging are slow tumor accumulation and high background signal in the reticuloendothelial system, which may be overcome by peptide, small molecule, or antibody fragment-based tracers since they typically exhibit fast blood clearance. Highaffinity CD105-binding peptides could be generated from various high-throughput screening strategies such as phage display. Anti-CD105 antibody fragments, both human and murine [38, 39] , as well as certain bispecific antibodies [40, 41] , may also be investigated in the future for imaging and potential therapeutic applications. Lastly, quantitative correlation of PET tracer uptake with CD105 expression level would be highly desirable for future treatment monitoring applications, as it would be ideal to noninvasively measure the changes of CD105 expression quantitatively, rather than qualitatively, in each individual patient upon antiangiogenic therapies.
Conclusion
We have successfully investigated 64 Cu-labeled TRC105, a human/murine chimeric antibody recognizing human and murine CD105, both in vitro and in vivo. MicroPET imaging revealed fast, prominent, persistent, and CD105-specific uptake of the tracer in the 4T1 tumor which was further validated by in vitro and ex vivo experiments. Since TRC105 is already in clinical investigation and therapeutic efficacy has been shown in various animal tumor models and certain cancer patients, this study identifies a new perspective for tumor angiogenesis-related research and warrants future clinical translation of 64 Cu-DOTA-TRC105, where it may be used to evaluate the pharmacokinetics, tumor targeting efficacy, dose optimization, and dose interval of TRC105 and TRC105-based cancer therapeutics in the clinic.
